EBM & Health Tech Assess (HTA)

A Rough Guide to Evidence-Based Medicine

A Shift Toward Specialty Meds – What Does This Mean For The U.S.?

Absence of evidence Vs Evidence of absence

Thought-provoking article suggesting that evidence-based medicine today has become evidence-burdened instead. (Source: Hegde, Mangalorean.com, Nov. 2009)

Adapting to Evolving Global Evidence Requirements in Medical Device Development Programs

AMCP Format for Formulary Submissions

A Format for Submission of Clinical and Economic Evidence of Pharmaceuticals in Support of Formulary Consideration. FMCP Format Executive Committee. (Source: Journal of Managed Care Pharmacy, Jan. 2010)

An Analysis of NICE ‘Restricted’ (or ‘Optimized’) Decisions

Article examins the attempt to develop a robust and defensible means of measuring and describing the degree of patient access in mixed NICE decisions.(Source: Pharmacoeconomics, O'Neill et al)

An international registry of systematic-review protocols

Support for prospective registration of protocols for systematic reviews has been gathering momentum and this article review the PRISMA statement, a guideline for reporting systematic reviews and meta-analyses of studies that evaluate health-care interventions, advocates registration. (Source: Lancet, July 2010)

Anecdotes Are Weak Evidence

DB Wright comments on a recent editorial by Dr. Norbert Gleicher in The Wall Street Journal that roundly criticizes the proposed role of expert panels.(Source: D. Brad Wright, Huffinton Post, Oct 2009)

Are all clinical trial results wrong?

Dr. John Ioannidis is known as a meta-researcher, and he's become one of the world's foremost experts on the credibility of medical research. He and his team have shown that much of what biomedical researchers conclude in published studies is misleading, exaggerated, and often flat-out wrong.(Source: World of DTC Marketing)

Are Metrics Blinding Our Perception?

In the Age of Metrics, vocation after vocation is discovering numbers. Doctors are going quant with evidence-based medicine, which promises to improve care by quantifying different treatments’ probabilities of success. (NYT, Nov. 21. 2009)

Are U.S. Cancer Patients Receiving Better Care Than Europeans?

Assessing Competency In Evidence Based Medicine

BIG DATA – Where Are We And What Does The Future Hold?

Can Big Data Help Fix Medical Research?

Centralized Vs. Decentralized HTA: Which is Better in Supporting Value-Based Pricing and Managed Entry of Pharmaceuticals and New Technologies?

Don Husereau, BScPharm, MSc, Adjunct Professor, Faculty of Medicine, University of Ottawa and Senior Scientist, University for Health Sciences, Medical Informatics and Technology, Tirol, Austria, ISPOR Washington DC, 2012.

Closing the Quality Gap Series. Through the Quality Kaleidoscope: Reflections on the Science and Practice of Improving Health Care Quality

AHRQ Report summarizes the knowledge of eight Evidence-based Practice Centers (EPCs) to synthesize lessons learned and to advance the state of QI science. Includes effectiveness of bundled payment programs, patient-centered medical home, adherence interventions, and public reporting, as well as QI strategies to address health disparities, prevention of healthcare-associated infections, QI measurement of disabilities, and for patients with advanced and serious illness.

Closing the Quality Gap Series. Through the Quality Kaleidoscope: Reflections on the Science and Practice of Improving Health Care Quality

AHRQ Report summarizes the knowledge of eight Evidence-based Practice Centers (EPCs) to synthesize lessons learned and to advance the state of QI science. Includes effectiveness of bundled payment programs, patient-centered medical home, adherence interventions, and public reporting, as well as QI strategies to address health disparities, prevention of healthcare-associated infections, QI measurement of disabilities, and for patients with advanced and serious illness.

Comparing the Effectiveness of New Drugs: Should the FDA Be Asking More Questions?

by Sean R. Tunis, MD, MSc, President & CEO, Center for Medical Technology Policy, Baltimore, MD, USA, ISPOR Washington DC, 2012.

Comparisons Of FDA And EMA Risk Management Requirements For Recently Approved Products

Overview of Risk Evaluation and Mitigation Strategies (REMS) and Risk Management Plans (RMPs) in US and Europe.

Complimentary Real World Evidence Case Study Dossier Download Available

Confused About How to Gain Optimal Access in Canada?

Convergence or Divergence in Health Technology Assessment.

PPT Presentation by Longson, Presented at ISPOR Berlin 2012.

Core principles on relative effetiveness

The core principles on relative effectiveness assessments set out certain general principles of public administration that could be relevant for developing national systems and help to encourage of exchange of information, methodologies and experiences between the relevant national authorities.

Creating a Framework for “Best Evidence” Approaches in Systematic Reviews

This creates a decision framework for "best evidence" approaches in systematic reviews. This will be Phase I of a larger project (Phase II would involve a formal evaluation of the impact of variations in inclusion criteria on a review's conclusions).

Dartmouth Atlas of Health Care

Provides data on regional costs and spending for healthcare. Website provides access to all Atlas reports and publications, as well as interactive tools to allow visitors to view specific regions and perform their own comparisons and analyses.

David Eddy Delivers Controversial Lecture on the Future of EBM

Kent Bottles discusses David Eddy's history and recent speech in this posting. (Source: ICSI Health Care Blog, Nov. 30, 2009)

Developing and Testing a Tool for the Classification of Study Designs in Systematic Reviews of Interventions and Exposures

Emphasis on understanding the comparative effectiveness of health care interventions has increased attention on the applicability of research. As a result, systematic reviews aiming to inform clinical practice have expanded beyond randomized controlled trials, which have limited generalizability, to include nonrandomized studies

Discussion Lists on Evidence Based Health: How to join

National Academic Mailing List Service, known as 'JISCMail', is a service designed specifically for the further and higher education and research communities and is one of a number of services provided by JISC Advance therefore making it the foremost strategic collaboration tool within the academic community.

Do Decision Support Tools Make Docs Look Dumb?

Does Health Economics Have A Role In The New Era Of Personalized Medicine?

Categories

Stay Connected